Clinical Observation of Polycystic Ovary Syndrome Treatment with Resveratrol

Abstract

The fundamental target of the present survey is to explore the clinical impact of resveratrol in treating polycystic ovary syndrome. A number of 104 cases suffering from polycystic ovary syndrome admitted to the hospital from January 2018 to December 2020 were chosen as investigation subjects. The cases were categorized into two groups, namely control and study groups through the random number table technique, with 52 patients in each group. Patients in the group of study were considered to receive 100 % pure resveratrol (once daily, 1000 mg) and cases in the group of control received matched placebo. 3 mo later, the treatment effects of the two groups were scrutinized. Following the treating process, the length of ovary, endometrial thickness and number of sinus follicles in the research group were improved and substantially superior to those in the group of control (all p<0.05). The improvement in menstrual cycle and hair loss in the group of observation was considerably greater than that in the group of control (both p<0.05). Following the treatment, the levels of luteinizing hormone, estradiol and testosterone in the group of observation were less than those in the group of control, with statistically meaningful discrepancies (all p<0.05), but the follicle-stimulating hormone levels had no significant difference. After 3 mo of treating, the expression level of mitofusin-2 in the study group was substantially enhanced in comparison to that in the control group (p<0.05). Resveratrol improved sex hormone levels, menstrual irregularities, hair loss and ovarian function in cases suffering from polycystic ovary syndrome.